September 05, 2024

ERC Starting Grant for DKFZ researcher Jens Puschhof

ERC Starting Grant for DKFZ researcher Jens Puschhof

Funding from the European Research Council (ERC) is regarded as an accolade for scientists at all career stages. With its “Starting Grants”, the ERC aims to pave the way to an independent career for excellent young researchers. This year, Jens Puschhof from the German Cancer Research Center (DKFZ) has been awarded the prestigious grant. The funding will enable Puschhof to investigate the role played by bacteria that colonize cancer metastases in the spread of the tumour in the body. The results could reveal new ways of containing or preventing dangerous cancer metastases.

Jens Puschhof © J. Jung/DKFZ

With its ERC Starting Grants, the European Research Council (ERC) supports talented young scientists. The funding of 1.5 million euros for up to five years is intended to help them set up their own research group at a recognized research institution in the EU.

Bacterial colonization has already been proven for a large number of types of cancer. The case is particularly clear for colorectal cancer, as examinations of stool and tissue have repeatedly and reliably shown a connection with certain types of bacteria.

The bacterial colonization of cancer metastases has been far less investigated. Several studies indicate the presence of microorganisms in the metastases of tumors, such as breast or colon cancer. Whether, and if so, what role the microbes play in the metastasis process, however, is virtually unknown. Yet metastatic spread is the main cause of cancer mortality and understanding the role of bacteria in this process could reveal new ways of stopping or interrupting this progression.

With the ERC-funded METABAC project, Jens Puschhof wants to systematically tackle these questions on the example of colorectal cancer metastases. The first step is to catalog exactly which types of bacteria actually colonize the metastases. In a next phase, Puschhof’s team wants to find out whether the respective microorganisms influence certain aspects of cancer spread. In these investigations, the DKFZ team will benefit from its extensive expertise with sophisticated methods developed in-house, such as the co-culture of tumor organoids with bacteria or organ-on-a-chip techniques.

Junior Research Group Epithelium Microbiome lnteractions © DKFZ

The key questions that Puschhof wants to answer are: Do the bacteria isolated from metastases have special genetic properties that distinguish them from their counterparts from the primary tumor or from healthy tissue? Do they contribute to the metastasis? How do they reach the distant sites deep inside the body, for example, do they travel inside the cancer cells? And do they play a role in the localization of metastases in different organs?

The results of the METABAC project will be directly incorporated into translational research projects to find out how cancer patients can benefit from research progress as quickly as possible.

After studying molecular biotechnology and oncology in Heidelberg, Harvard and Oxford, Jens Puschhof moved to the laboratory of Hans Clevers at Utrecht University for his doctoral thesis. In 2022, he founded the “Epithelium Microenvironment Interaction Laboratory” research group within the Division of Microbiome and Cancer at the DKFZ, which was transformed into an independent junior research group in 2024. In 2023, Puschhof was awarded the Young Investigator Award for Cancer Prevention Research.

A photo of Jens Puschhof is available for download: https://www.dkfz.de/de/presse/pressemitteilungen/2024/bilder/Puschhof.jpg 

Note on the use of image material for press releasesUse is free of charge. The German Cancer Research Center (DKFZ) permits use in connection with reporting on the topic of the press release or on the DKFZ in general. Please indicate as picture credits: “Source: J. Jung / DKFZ”.The image may only be passed on to third parties after prior consultation with the DKFZ Press Office (Tel. 06221 42 2854, e-mail: presse@dkfz.de). Use for commercial purposes is prohibited.

Original News

Our latest News

discover more
BioMed X and Servier Launch First XSeed Labs in Europe

BioMed X and Servier Launch First XSeed Labs in Europe

Heidelberg, Germany / Paris, France, July 9th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe […]

Investigating kinase activity in living cells

Investigating kinase activity in living cells

Scientists build molecular recording tool The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research in Heidelberg have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This […]

The evolution of cancer cells decoded

The evolution of cancer cells decoded

Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp